Skip to main content

NIA Funding Line Policy for FY 2018

NIA received a full year appropriation on March 23, 2018 of $2.574 billion, a $526 million increase over the FY 2017 level. The amount includes an additional $414 million for Alzheimer’s Disease research funding – including Alzheimer’s disease-related dementias.

NIH published the Fiscal Policy for Grant Awards – FY 2018 on May 16, 2018. Consistent with that policy, NIA is fully restoring cuts in non-competing awards made during prior continuing resolutions and paying future FY 2018 non-competing awards at the commitment level indicated on the Notice of Award.

NIA Competing Award Funding Policy

General Allocation: NIA is continuing a policy of holding to an average reduction of 18% on all competing research grant awards within the general allocation, with the exceptions of small grants awards (R03) and exploratory/developmental awards. These latter awards generally receive the study-section recommended amount of support. The 18% cut is an average. Individual awards are being reduced by more, or less than, that amount.

Alzheimer’s Allocation: NIA is awarding the study-section recommended amount of support within the Alzheimer’s allocation but with adjustments as deemed appropriate by staff.

September 2018 Update

NIA is reducing the average administrative cut on awards to 12% from 18%. This change affects all competing awards for FY 2018, both those already made and those yet to be made. As previously, NIA is not making administrative cuts to small grants (R03) or to exploratory/developmental awards (R21). These changes are to the average size of the cut. Individual awards may be cut by more, or less, than that amount.

General Allocation Update: Revised Funding Lines

NIA is paying most applications to the lines indicated. NIA may skip a few applications or award them R56 grants where consensus exists that the application needs to be improved prior to award. Similarly, NIA may pay a few applications beyond the funding line where any identified weaknesses may be addressed easily and the proposed research fits NIA’s published priorities.

CSR-reviewed Research Applications
  General Pay line, < 500k General Pay line, ≥ 500k ADRD pay line, < 500k ADRD pay line ≥ 500k
All (except below) 23% 20% 28% 25%
New Investigator R01s 26% 23% 31% 28%
Early Stage Investigator R01s 29% 26% 33% 30%

 

NIA-reviewed Research Applications
  General pay line ADRD pay line
Program projects 33 38
Other NIA-reviewed research 33 38

 

Training-related Applications
  General pay line ADRD pay line
Training grants 21 35
Career awards 21 28
Fellowships 28 32

May 2018 Update

The tables below show NIA funding lines for FY 2018 for both the general allocation and for the Alzheimer’s allocation (which includes applications on dementias related to Alzheimer’s disease). The tables do not show funding lines for initiatives with set-asides. Contact your program officer for information on these applications.

We are paying most applications to the funding lines shown. For individual reasons, some applications within these lines may not be paid this year.

CSR-reviewed Research Applications
  General Pay line, < 500k General Pay line, ≥ 500k ADRD pay line, < 500k ADRD pay line ≥ 500k
All (except below) 19% 16% 28% 25%
New Investigator R01s 22% 19% 31% 28%
Early Stage Investigator R01s 25% 22% 33% 30%

 

NIA-reviewed Research Applications
  General pay line ADRD pay line
Program projects 31 38
Other NIA-reviewed research 31 38

 

Training-related Applications
  General pay line ADRD pay line
Training grants 21 35
Career awards 20 28
Fellowships 28 32